ARC West’s funding ended on 31 March 2026. This site is an archive and is no longer updated.
Evaluating the benefit of early patient and public involvement for product development and testing with small companies
Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane
Should I stay or should I go? A qualitative exploration of stigma and other factors influencing opioid agonist treatment journeys